Compare SUNS & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | ALDX |
|---|---|---|
| Founded | 2023 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7M | 124.9M |
| IPO Year | N/A | 2014 |
| Metric | SUNS | ALDX |
|---|---|---|
| Price | $8.44 | $1.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $8.75 | $5.50 |
| AVG Volume (30 Days) | 137.4K | ★ 2.1M |
| Earning Date | 05-14-2026 | 05-01-2026 |
| Dividend Yield | ★ 16.17% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $70.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.34 | $1.07 |
| 52 Week High | $11.78 | $6.18 |
| Indicator | SUNS | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.67 | 38.70 |
| Support Level | $7.39 | $1.49 |
| Resistance Level | $8.86 | $1.91 |
| Average True Range (ATR) | 0.28 | 0.19 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 57.40 | 6.45 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.